Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 5/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.96 |
| ▸ | DRD3 | P35462 | 6/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.96 |
| ▸ | HTR1A | P08908 | 5/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.96 |
| ▸ | HRH1 | P35367 | 5/20 | 0.96 |
| ▸ | DRD1 | P21728 | 5/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.96 |
| ▸ | HTR2C | P28335 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiothixene SCHEMBL30903897 | 1.00 | MEN1 (0.98) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL561321 | 0.99 | MEN1 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL34305 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL29373233 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL782605 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL29391417 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL3715363 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL718331 | 0.98 | CYP3A4 (1.00) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL721093 | 0.97 | CYP3A4 (0.94) | MEN1KMT2ANR1I2NPSR1LMNA | |
| Thiothixene SCHEMBL8022212 | 0.94 | CYP3A4 (0.91) | MEN1KMT2ANR1I2NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2883 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | claimed |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | MUELLER NORBERT | 2011-06-02 | — | — | US | claimed |
| EP-1627639-B1 | Use of COX-2 inhibitors for the treatment of affective disorders | MUELLER NORBERT (DE) | 2009-12-23 | — | — | EP | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| EP-2032124-A1 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2009-03-11 | — | — | EP | claimed |
| US-20090004281-A1 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2009-01-01 | — | — | US | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2008001341-A1 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2008-01-03 | — | — | WO | claimed |
| US-20040121015-A1 | Controlled-Release of an active substance into a high fat environment | PFIZER INC | 2004-06-24 | — | — | US | claimed |
| EP-1397145-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | Müller, Norbert (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |